Isotope-Labeled Sphingolipids

C18:0-d₇ GD3 Ceramide (d₁₈:1/18:0-d₇) is deuterium labeled C18:0 GD3 Ceramide (d18:1/18:0).

EOP (t18:0/28:0/18:2)-d₁₁ is deuterium labeled EOP (t18:0/28:0/18:2).

EOS (d18:1/32:0/18:2)-d₉ is the deuterium labeled EOS (d18:1/32:1/18:2) (HY-139393). EOS (d18:1/32:1/18:2) is a kind ceramide in the outer epidermis.

C6 Ceramide-¹³C₂,d₂ (C6-Cer-¹³C₂,d₂) is the deuterium labeled and ¹³C-labeled C6 Ceramide (HY-19542). C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects.

CER3-d₃ is the deuterium labeled CER3.

N,N-Dimethylsphingosine-¹³C₂ is the ¹³C-labeled N,N-Dimethylsphingosine (HY-108491). N,N-Dimethylsphingosine is a sphingosine kinase inhibitor. N,N-Dimethylsphingosine binds competitively to sphingosine kinase and blocks the conversion of sphingosine to sphingosine-1-phosphate. N,N-Dimethylsphingosine inhibits sphingosine-1-phosphate release and aggregation of platelets, and also exerts pro-apoptotic effects by resetting ceramide/sphingosine-1-phosphate homeostasis. N,N-Dimethylsphingosine can be used in cancer-related research.

N-Octadecanoyl-sulfatide-d₃ is deuterium labeled N-Octadecanoyl-sulfatide. N-Octadecanoyl-sulfatide is an ester product.

C16-Ceramide-¹³C₁₆ is a ¹³C-labeled C16-Ceramide (HY-100354).